Last reviewed · How we verify
Azienda Sanitaria dell'Alto Adige — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Fentanyl ev | Fentanyl ev | marketed | Synthetic opioid agonist | Mu-opioid receptor (OPRM1) | Pain management, Anesthesia |
Therapeutic area mix
- Pain management, Anesthesia · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Boston Medical Center · 1 shared drug class
- L'Hospitalet de Llobregat · 1 shared drug class
- Oregon Health and Science University · 1 shared drug class
- University Hospital, Ghent · 1 shared drug class
- University of Maryland, Baltimore · 1 shared drug class
- Virginia Commonwealth University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Azienda Sanitaria dell'Alto Adige:
- Azienda Sanitaria dell'Alto Adige pipeline updates — RSS
- Azienda Sanitaria dell'Alto Adige pipeline updates — Atom
- Azienda Sanitaria dell'Alto Adige pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Azienda Sanitaria dell'Alto Adige — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-sanitaria-dell-alto-adige. Accessed 2026-05-17.